Abstract Submission for Designated Sessions
Please refer to the following guidelines and submit your abstracts by accessing the submission system by clicking the "Abstract Submission" button located at the bottom of this page.
Abstract Submission Guidelines
- Author information and abstracts must be submitted in English.
- Abstract title is limited to 150 single-byte characters. (including spaces)
- Abstract is limited to 2,000 single-byte characters. (including spaces)
- A maximum of 20 authors (first author & co-authors) may be registered.
- A maximum of 20 affiliations (including the affiliation of the first author) may be registered.
- Charts or diagrams cannot be included.
- Regarding the special characters, please refer ‘How to type special characters’ in the registration page.
Publication in "Annals of Oncology"
English abstracts submitted for JSMO2021 will be published in the ESMO/JSMO Scientific Journal, supplement to "Annals of Oncology" (Elsevier).
If you wish to have your abstract published in "Annals of Oncology," please select "Yes".
* Note: We are accepting encore abstracts, which includes abstracts that pose a new view on a particular topic or present updated data with subset analysis. However, if your abstract is an encore abstract, it cannot be included in "Annals of Oncology"- therefore please select "No".
Disclosure of Conflict of Interest at 2021 the Japanese Society of Medical Oncology Annual Meeting
The presenter (the first author) and the principal investigator must disclose the name(s) of any company(s) or for-profit organization(s) for which there are relationships related to their presentation. Potential relationships are defined in items (3) to (9), (11), and (12), direct relationships are described in items (1), (2), (10), (13) if met. The subject period is from January 1, 2017 - December 31, 2019.
COI Policy (in revision)
Detailed Enforcement Regulations of COI (in revision)
For your presentation, please include your COI disclosures on your second slide. You may use the template slide below as a reference.
(1) |
If your study for this presentation is supported by research funds |
|---|---|
(2) |
If you are or have been an employee of a company and/or a profit-making organization related to medicine |
(3) |
If you have earned ＞￥1,000,000/year as an officer or advisor of a company and/or a profit-making organization related to medicine |
(4) |
If you hold＞5％ of the stock of a company and/or a profit-making organization related to medicine, or receive dividends ＞￥1,000,000/year |
(5) |
If you have earned ＞￥1,000,000/year as a patent fee from a company and/or a profit-making organization related to medicine |
(6) |
If you have earned ＞￥500,000/year as a lecture fee from a company and/or a profit-making organization related to medicine |
(7) |
If you have earned ＞￥500,000/year as a manuscript fee from a company and/or a profit-making organization related to medicine |
(8) |
If you have research expenses ＞￥1,000,000/year from a company and/or a profit-making organization related to medicine |
(9) |
If you have received ＞￥1,000,000/year as a certain contribution from a company and/or a profit-making organization related to medicine |
(10) |
If you are or have been involved in a certain endowed chair funded by a company and/or a profit-making organization related to medicine |
(11) |
If you have ＞￥1,000,000/year as a fee for expert comment, judgment or testimony in legal proceedings, or others from a company and/or a profit-making organization related to medicine |
(12) |
If you have received remuneration (travel, gifts, or other in-kind payments not directly related to research）equivalent to ＞￥50,000/year from a company and/or a profit-making organization related to medicine |
(13) |
If you are a representative of an organization for clinical study which receives research expenses（donation, contract, others）from a company and/or a profit-making organization related to medicine |
To view the PDF files, you may need, "Adobe Reader"(Download Adobe Reader)
Inquiries regarding COI disclosure
The Secretariat of the Japanese Society of Medical Oncology
E-mail: 
Ethical Principles for Declaring Ethical Matters of Your Abstract
In order to ensure that your abstract conforms to the standard of applicable research ethics such as "GCP", "GPSP", "Ethical guidelines on medical research on humans", "Ethical guidelines on research on human genome and gene analysis", etc., JSMO asks you to declare the following items:
- Does your study include medical research on human subjects, human material or human data? *Required
- Does your study comply with the Declaration of Helsinki?
- Was your study approved by an institutional review board before starting the research?
Declarations of these items will not affect the acceptance or rejection of your abstract.
Abstract Submission Page
Confirmation / Modification / Deletion of Submitted Abstract & Additional Submission Page
Inquiries for Abstract Submission
Congress Secretariat
c/o Congrès Inc.
3-6-13, Awajimachi, Chuo-ku, Osaka, 541-0047, Japan
E-mail: jsmo2021-endai@congre.co.jp
